Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 7, Issue 5, 2010, Pages 331-336

  Vestbo, Jørgen ^a   Vogelmeier, Claus ^b   Creemers, Jacques ^c   Falques, Meritxell ^d   Ribera, Anna ^d   Gil, Esther Garcia ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c CATHARINA HOSPITAL   (Netherlands)

^d R and D Centre ^*  (Spain)

Author keywords

Aclidinium bromide; Bronchodilation; Chronic obstructive pulmonary disease; Muscarinic antagonist; Onset of action

Indexed keywords

ACLIDINIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPIROMETRY;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; TIME FACTORS; TREATMENT OUTCOME; TROPANES;

EID: 77956957659     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2010.510158     Document Type: Article

References (16)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
2. Gavalda A, Miralpeix M, Ramos I, Otal R, Carreno C, Vinals M, Domenech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009; 331:740-751.
3. Gavaldà A, Sentellas S, Alberti J, Anton SF, Salva M, Beleta J. Aclidinium bromide, a novel long-acting anticholinergic, is rapidly inactivated in plasma. Am J Respir Crit Care Med 2008; 177 (Abstract Issue): A-654.
4. Chanez P, Burge PS, Dahl R. Aclidinium bromide provides longacting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2009; Epub ahead of print 14 August.
5. Jansat JM, Lamarca R, Garcia-Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel longacting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009; 47:460-468.
6. Joos GF, Schelfhout VJ, Kanniess F, Ludwig-Sengpill A, Garcia Gil E, Montejo EM. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a Phase II study. Eur Respir J 2007; 30 (Suppl 51):210S.
7. Schelfhout VJ, Joos GF,GarciaGil E, Montejo EM. Bronchodilator/ bronchoprotective effects of aclidinium bromide, a novel longacting anticholinergic: a Phase I study. Eur Respir J 2007; 30(Suppl 51):356S.
8. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5-40.
9. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, Van Der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948-968.
10. Calverley PMA, Burge PS, Spencer S, Anderson J, Jones P, for the ISOLDE Study Investigators. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-664.
11. Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE, for the Lung Health Study Research Group. Bronchodilator response in the lung healthy study over 11 yrs. Eur Respir J 2005; 26:45-51.
12. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:1267-1271.
13. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31:416-469.
14. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ, for the Dutch Tiotropium Study Group. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55:289-294.
15. van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJG. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19:639-644.
16. Casaburi R, Porszasz J. Reduction of hyperinflation by pharmacologic and other interventions. Proc Am Thorac Soc 2006; 3:185-189.